Early success of the COCOON trial: Preventing dermatologic adverse events in first-line EGFR-mutant NSCLC (IMAGE)
Caption
Figure 2
Incidence of moderate-to-severe dermatologic adverse events by category and body site during the first 12 weeks of treatment.
Prophylactic dermatologic management (blue bars) dramatically reduced the occurrence of significant rash on the face/body and scalp, and slightly reduced nail inflammation, compared to standard reactive care (gray bars). Each bar represents the percentage of patients withgrade ≥2 AEs in that category (e.g., acneiform rash on face/body, scalp AEs, or paronychia). Prophylaxis conferred a 63% reduction in face/body rash and a 69% reduction in scalp AEs. All differences shown favored the COCOON prophylaxis arm.
Credit
Copyright: © 2026 Tiwari and Koirala. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Usage Restrictions
With credit to the original source.
License
Original content